Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, a potential ...

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange ...

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

The U.S. Food and Drug Administration announced last week that a pharmaceutical company is removing a fentanyl patch from ...

Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall is that there is a potential that patches ...

A mid-stage study reveals that transdermal estradiol patches may match traditional androgen deprivation therapy in treating prostate cancer with fewer side effects. This approach boosts bone density ...

Application of a multi-stacked fentanyl patch could result in serious, life-threatening, or fatal respiratory depression.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Alvogen has issued a nationwide recall of one lot of Fentanyl Transdermal System 25 patches because the patches may stick ...

The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe ...